

CLAIMS

1. Polymorph 1 of bilastin characterised by X-ray crystallography analysis with crystal parameters of approximately the following:

5

Crystallograph system	Monoclinical		
Spatial group	P2 (1)/c		
Crystal size	0.56 x 0.45 x 0.24 mm		
Cell dimension	$a=23.38 (5)$ Å	angstrom	$\alpha = 90^\circ$
	$b=8.829 (17)$ Å		$\beta = 90^\circ$
	$c=12.59 (2)$ Å		$\gamma = 90^\circ$
Volume	2600 \AA^3		
Z, calculated density	$4, 1.184 \text{ mg/m}^3$		

15 2. Polymorph 1 of bilastin according to Claim 1, distinguished in that it has
an infrared spectrum in potassium bromide with the following bands:

Wavelength (cm⁻¹)

3057

20 2929

2883

2857

2797

1666

25 1481

1431

1346

1326

1288

973

945

829

5 3. Polymorph 1 of bilastin according to Claim 1, distinguished because it has an infrared spectrum in potassium bromide like the one shown in Figure 1.

10 4. Procedure to prepare polymorph 1 of bilastin according to Claims 1, 2 and 3 that consists in heating the bilastin obtained as described in US patent 5,877,187 in a solvent selected from short chained alcohols, preferably isopropyl alcohol and n-butanol, acetone and its mixtures.

15 5. Procedure to prepare polymorph 1 from bilastin according to Claims 1, 2 and 3 that consists in heating polymorphs 2 and 3 of bilastin or its mixtures, in a solvent selected from short chained alcohols, preferably isopropyl alcohol and n-butanol, acetone and its mixtures.

20 6. Polymorph 1 of bilastin according to Claim 1 for antihistaminic and antiallergic use.

25 7. Polymorph 1 of bilastin according to Claim 2 for antihistaminergic and antiallergic use.

 8. Polymorph 1 of bilastin according to Claim 3 for antihistaminergic and antiallergic use.

9. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 1 and an acceptable pharmaceutical excipient.

5 10. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 2 and an acceptable pharmaceutical excipient.

10 11. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 3 and an acceptable pharmaceutical excipient.

15 12. Use of polymorph 1 of bilastin according to Claim 1 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.

13. Use of polymorph 1 of bilastin according to Claim 2 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.

20 14. Use of polymorph 1 of bilastin according to Claim 3 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.